Moderna (MRNA) PT Lowered to $130 at BofA Securities
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $142.65 -4.68%
Rating Summary:
6 Buy, 22 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 18
Rating Summary:
6 Buy, 22 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 18
Join SI Premium – FREE
BofA Securities analyst Geoff Meacham lowered the price target on Moderna (NASDAQ: MRNA) to $130.00 (from $150.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Wolfe Research Upgrades Moderna (MRNA) to Peerperform
- Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
